As it awaits regulatory clearance for its Tumor Treating Fields technology in non-small cell lung cancer—and in the wake of the technology’s recent trial failure in ovarian disease—Novocure is narrowing its workforce and its pipeline to help conserve funds.
https://www.fiercebiotech.com/medtech/novocure-lays-200-workers-plan-shave-60m-expenses